About regeneron pharmaceuticals inc. - REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
REGN At a Glance
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591-6707
| Phone | 1-914-847-7000 | Revenue | 14.20B | |
| Industry | Pharmaceuticals: Major | Net Income | 4.41B | |
| Sector | Health Technology | 2024 Sales Growth | 8.27% | |
| Fiscal Year-end | 12 / 2025 | Employees | 15,106 | |
| View SEC Filings |
REGN Valuation
| P/E Current | 17.764 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 18.581 |
| Price to Sales Ratio | 5.773 |
| Price to Book Ratio | 2.66 |
| Price to Cash Flow Ratio | 18.55 |
| Enterprise Value to EBITDA | 16.302 |
| Enterprise Value to Sales | 5.345 |
| Total Debt to Enterprise Value | 0.039 |
REGN Efficiency
| Revenue/Employee | 940,156.229 |
| Income Per Employee | 292,109.096 |
| Receivables Turnover | 2.286 |
| Total Asset Turnover | 0.40 |
REGN Liquidity
| Current Ratio | 4.731 |
| Quick Ratio | 3.948 |
| Cash Ratio | 2.285 |
REGN Profitability
| Gross Margin | 82.739 |
| Operating Margin | 29.389 |
| Pretax Margin | 33.657 |
| Net Margin | 31.07 |
| Return on Assets | 12.433 |
| Return on Equity | 15.951 |
| Return on Total Capital | 13.665 |
| Return on Invested Capital | 14.466 |
REGN Capital Structure
| Total Debt to Total Equity | 10.012 |
| Total Debt to Total Capital | 9.101 |
| Total Debt to Total Assets | 7.764 |
| Long-Term Debt to Equity | 9.908 |
| Long-Term Debt to Total Capital | 9.007 |
Regeneron Pharmaceuticals Inc. in the News
Regeneron Pharmaceuticals to buy bankrupt 23andMe in $256M deal
Genetic testing company 23andMe filed for Chapter 11 bankruptcy protection in March. Regeneron Pharmaceuticals announced it would buy "substantially all" of 23andMe's assets.
Merck COVID-19 pill success slams Moderna shares, shakes up health care sector
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies.